In this episode we're joined by GSK's Head of Market Access for General Medicines, Rupert Gale.

Rupert has been in pharma for over 27 years and is still going strong! In this discussion, he shares what resilience means to him and why he feels it's an important skill for market access leaders to leverage.

Rupert shares some wonderful stories and advice that many of us can relate to and learn from. He also reveals what's keeping him passionate about access and value as he continues his career journey.

The views shared in this episode are Rupert's own opinions and not representative of the company he is working for.

Korinna Karampampa, who is Director Market Access and Pricing at CSL Behring, joins this episode to share her views on sustainable economic development.

Korinna shares what led her into market access and explains what drives her to think outside the box to build and demonstrate a product's current and future value.


The opinions shared in this episode are Korinna’s own views and not representative of the organisation she is working for.

In this episode we're joined by our first guest from Biotech - Ning Lu, who is Associate Director, International Pricing & Market Access at Blueprint Medicines.

Ning shares her views on the complexities of market access and what makes the Biotech industry unique. She shares what inspired her to pursue a career in market access in biotechnology and why she feels it's a dynamic role and opportunity to 'connect the dots' with everything you learn.

Ning references and recommends the book "Science Business: The promise. The reality. And the future of biotech." By Gary Pisano. More information on this title is available here. https://amzn.eu/d/5nfsQVA

The opinions shared in this episode are Ning’s own views and not representative of the organisation she is working for.